Pharmacologic Agents for the Treatment of Vasodilatory Shock

Author(s): Hans Knotzer*, Bernhard Poidinger, Axel Kleinsasser.

Journal Name: Current Pharmaceutical Design

Volume 25 , Issue 19 , 2019


Abstract:

Vasodilatory shock is a life-threatening syndrome in critically ill patients and is characterized by severe hypotension and resultant tissue hypoperfusion. This shock state requires the use of vasopressor agents to restore adequate vascular tone.

Norepinephrine is still recommended as first-line vasopressor in the management of critically ill patients suffering from severe vasodilation. In the recent time, catecholaminergic vasopressor drugs have been associated with possible side effects at higher dosages. This so-called catecholamine toxicity has focused on alternative noncatecholaminergic vasopressors or the use of moderate doses of multiple vasopressors with complementary mechanisms of action. Besides vasopressin and terlipressin, angiotensin II may be a promising drug for the management of vasodilatory shock. In addition, adjunctive drugs, such as hydrocortisone, methylene blue or ascorbic acid can be added to conventional vasopressor therapy.

The objective of this review is to give an overview of the current available vasopressor agents used in vasodilatory shock. A thorough search of PubMed was conducted in order to identify the majority of studies related to the subject. Data on the outcome of several drugs and future perspective of possible management strategies for the therapy of vasodilatory shock are discussed.

Keywords: Vasopressin, Terlipressin, Angiotensin II, Norepinephrine, Methylene Blue, Vasopressors, Epinephrine.

[1]
Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013; 41(2): 580-637.
[http://dx.doi.org/10.1097/CCM.0b013e31827e83af] [PMID: 23353941]
[2]
Leone M, Asfar P, Radermacher P, Vincent JL, Martin C. Optimizing mean arterial pressure in septic shock: A critical reappraisal of the literature. Crit Care 2015; 19: 101.
[http://dx.doi.org/10.1186/s13054-015-0794-z] [PMID: 25888071]
[3]
Vincent JL, De Backer D. Circulatory shock. N Engl J Med 2013; 369(18): 1726-34.
[http://dx.doi.org/10.1056/NEJMra1208943] [PMID: 24171518]
[4]
Jentzer JC, Vallabhajosyula S, Khanna AK, Chawla LS, Busse LW, Kashani KB. Management of refractory vasodilatory shock. Chest 2018; 154(2): 416-26.
[http://dx.doi.org/10.1016/j.chest.2017.12.021] [PMID: 29329694]
[5]
Rhodes A, Evans LE, Alhazzani W, et al. Surviving sepsis campaign: International guidelines for management of sepsis and septic shock: 2016. Crit Care Med 2017; 45(3): 486-552.
[http://dx.doi.org/10.1097/CCM.0000000000002255] [PMID: 28098591]
[6]
Dünser MW, Hasibeder WR. Sympathetic overstimulation during critical illness: Adverse effects of adrenergic stress. J Intensive Care Med 2009; 24(5): 293-316.
[http://dx.doi.org/10.1177/0885066609340519] [PMID: 19703817]
[7]
Andreis DT, Singer M. Catecholamines for inflammatory shock: A Jekyll-and-Hyde conundrum. Intensive Care Med 2016; 42(9): 1387-97.
[http://dx.doi.org/10.1007/s00134-016-4249-z] [PMID: 26873833]
[8]
Asfar P, Meziani F, Hamel JF, et al. High versus low blood-pressure target in patients with septic shock. N Engl J Med 2014; 370(17): 1583-93.
[http://dx.doi.org/10.1056/NEJMoa1312173] [PMID: 24635770]
[9]
Mutlu GM, Factor P. Role of vasopressin in the management of septic shock. Intensive Care Med 2004; 30(7): 1276-91.
[http://dx.doi.org/10.1007/s00134-004-2283-8] [PMID: 15103461]
[10]
Maslow AD, Stearns G, Butala P, Schwartz CS, Gough J, Singh AK. The hemodynamic effects of methylene blue when administered at the onset of cardiopulmonary bypass. Anesth Analg 2006; 103(1): 2-8.
[http://dx.doi.org/10.1213/01.ane.0000221261.25310.fe] [PMID: 16790616]
[11]
Khanna A, English SW, Wang XS, et al. Angiotensin II for the treatment of vasodilatory shock. N Engl J Med 2017; 377(5): 419-30.
[http://dx.doi.org/10.1056/NEJMoa1704154] [PMID: 28528561]
[12]
Cecconi M, De Backer D, Antonelli M, et al. Consensus on circulatory shock and hemodynamic monitoring. Task force of the European Society of Intensive Care Medicine. Intensive Care Med 2014; 40(12): 1795-815.
[http://dx.doi.org/10.1007/s00134-014-3525-z] [PMID: 25392034]
[13]
Benbenishty J, Weissman C, Sprung CL, Brodsky-Israeli M, Weiss Y. Characteristics of patients receiving vasopressors. Heart Lung 2011; 40(3): 247-52.
[http://dx.doi.org/10.1016/j.hrtlng.2010.04.007] [PMID: 20630594]
[14]
Levy B, Collin S, Sennoun N, et al. Vascular hyporesponsiveness to vasopressors in septic shock: From bench to bedside. Intensive Care Med 2010; 36(12): 2019-29.
[http://dx.doi.org/10.1007/s00134-010-2045-8] [PMID: 20862451]
[15]
Maheshwari K, Nathanson BH, Munson SH, et al. The relationship between ICU hypotension and in-hospital mortality and morbidity in septic patients. Intensive Care Med 2018; 44(6): 857-67.
[http://dx.doi.org/10.1007/s00134-018-5218-5] [PMID: 29872882]
[16]
Annane D, Vignon P, Renault A, et al. Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: A randomised trial. Lancet 2007; 370(9588): 676-84.
[http://dx.doi.org/10.1016/S0140-6736(07)61344-0] [PMID: 17720019]
[17]
Myburgh JA, Higgins A, Jovanovska A, Lipman J, Ramakrishnan N, Santamaria J. A comparison of epinephrine and norepinephrine in critically ill patients. Intensive Care Med 2008; 34(12): 2226-34.
[http://dx.doi.org/10.1007/s00134-008-1219-0] [PMID: 18654759]
[18]
Russell JA, Walley KR, Singer J, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008; 358(9): 877-87.
[http://dx.doi.org/10.1056/NEJMoa067373] [PMID: 18305265]
[19]
De Backer D, Biston P, Devriendt J, et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 2010; 362(9): 779-89.
[http://dx.doi.org/10.1056/NEJMoa0907118] [PMID: 20200382]
[20]
Schmittinger CA, Torgersen C, Luckner G, Schröder DC, Lorenz I, Dünser MW. Adverse cardiac events during catecholamine vasopressor therapy: A prospective observational study. Intensive Care Med 2012; 38(6): 950-8.
[http://dx.doi.org/10.1007/s00134-012-2531-2] [PMID: 22527060]
[21]
Martin C, Medam S, Antonini F, et al. Norepinephrine: Not Too Much, Too Long. Shock 2015; 44(4): 305-9.
[http://dx.doi.org/10.1097/SHK.0000000000000426] [PMID: 26125087]
[22]
Belletti A, Musu M, Silvetti S, et al. Non-adrenergic vasopressors in patients with or at risk for vasodilatory shock. A systematic review and meta-analysis of randomized trials. PLoS One 2015; 10(11)E0142605
[http://dx.doi.org/10.1371/journal.pone.0142605] [PMID: 26558621]
[23]
Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 2016; 315(8): 801-10.
[http://dx.doi.org/10.1001/jama.2016.0287] [PMID: 26903338]
[24]
Serpa Neto A, Nassar AP, Cardoso SO, et al. Vasopressin and terlipressin in adult vasodilatory shock: A systematic review and meta-analysis of nine randomized controlled trials. Crit Care 2012; 16(4): R154.
[http://dx.doi.org/10.1186/cc11469] [PMID: 22889256]
[25]
Potter EK, Hodgson L, Creagh-Brown B, Forni LG. Manipulating the Microcirculation in Sepsis - the Impact of Vasoactive Medications on Microcirculatory Blood Flow. A Systematic Review. Shock 2019; 52(1): 5-12.
[http://dx.doi.org/10.1097/SHK.0000000000001239] [PMID: 30102639]
[26]
Tarazi RC. Sympathomimetic agents in the treatment of shock. Ann Intern Med 1974; 81(3): 364-71.
[http://dx.doi.org/10.7326/0003-4819-81-3-364] [PMID: 4605195]
[27]
Schaer GL, Fink MP, Parrillo JE. Norepinephrine alone versus norepinephrine plus low-dose dopamine: Enhanced renal blood flow with combination pressor therapy. Crit Care Med 1985; 13(6): 492-6.
[http://dx.doi.org/10.1097/00003246-198506000-00011] [PMID: 3996002]
[28]
Redfors B, Bragadottir G, Sellgren J, Swärd K, Ricksten SE. Effects of norepinephrine on renal perfusion, filtration and oxygenation in vasodilatory shock and acute kidney injury. Intensive Care Med 2011; 37(1): 60-7.
[http://dx.doi.org/10.1007/s00134-010-2057-4] [PMID: 20949349]
[29]
Evans T, Carpenter A, Kinderman H, Cohen J. Evidence of increased nitric oxide production in patients with the sepsis syndrome. Circ Shock 1993; 41(2): 77-81.
[PMID: 8242883]
[30]
Schneider AG, Goodwin MD, Schelleman A, Bailey M, Johnson L, Bellomo R. Contrast-enhanced ultrasonography to evaluate changes in renal cortical microcirculation induced by noradrenaline: A pilot study. Crit Care 2014; 18(6): 653.
[http://dx.doi.org/10.1186/s13054-014-0653-3] [PMID: 25439317]
[31]
Harrois A, Grillot N, Figueiredo S, Duranteau J. Acute kidney injury is associated with a decrease in cortical renal perfusion during septic shock. Crit Care 2018; 22(1): 161.
[http://dx.doi.org/10.1186/s13054-018-2067-0] [PMID: 29907130]
[32]
Gamper G, Havel C, Arrich J, et al. Vasopressors for hypotensive shock. Cochrane Database Syst Rev 2016; 2CD003709
[PMID: 26878401]
[33]
Avni T, Lador A, Lev S, Leibovici L, Paul M, Grossman A. Vasopressors for the Treatment of Septic Shock: Systematic Review and Meta-Analysis. PLoS One 2015; 10(8)E0129305
[http://dx.doi.org/10.1371/journal.pone.0129305] [PMID: 26237037]
[34]
Geloen A, Chapelier K, Cividjian A, et al. Clonidine and dexmedetomidine increase the pressor response to norepinephrine in experimental sepsis: A pilot study. Crit Care Med 2013; 41(12): E431-8.
[http://dx.doi.org/10.1097/CCM.0b013e3182986248] [PMID: 23963131]
[35]
Ince C, Mik EG. Microcirculatory and mitochondrial hypoxia in sepsis, shock, and resuscitation. J Appl Physiol 2016; 120(2): 226-35.
[http://dx.doi.org/10.1152/japplphysiol.00298.2015] [PMID: 26066826]
[36]
Lankadeva YR, Booth LC, Kosaka J, et al. Clonidine Restores Pressor Responsiveness to Phenylephrine and Angiotensin II in Ovine Sepsis. Crit Care Med 2015; 43(7): E221-9.
[http://dx.doi.org/10.1097/CCM.0000000000000963] [PMID: 25860204]
[37]
Miranda ML, Balarini MM, Bouskela E. Dexmedetomidine attenuates the microcirculatory derangements evoked by experimental sepsis. Anesthesiology 2015; 122(3): 619-30.
[http://dx.doi.org/10.1097/ALN.0000000000000491] [PMID: 25313879]
[38]
Prielipp RC, Royster RL, Spray BJ, Kon ND, Wallenhaupt SL, Zaloga GP. Dobutamine increases heart rate more than epinephrine in patients recovering from aortocoronary bypass surgery. J Cardiothorac Vasc Anesth 1992; 6: 535-41.
[http://dx.doi.org/10.1016/1053-0770(92)90095-O]
[39]
Jentzer JC, Coons JC, Link CB, Schmidhofer M. Pharmacotherapy update on the use of vasopressors and inotropes in the intensive care unit. J Cardiovasc Pharmacol Ther 2015; 20(3): 249-60.
[http://dx.doi.org/10.1177/1074248414559838] [PMID: 25432872]
[40]
Perkins GD, Ji C, Deakin CD, et al. A Randomized Trial of Epinephrine in Out-of-Hospital Cardiac Arrest. N Engl J Med 2018; 379(8): 711-21.
[http://dx.doi.org/10.1056/NEJMoa1806842] [PMID: 30021076]
[41]
Léopold V, Gayat E, Pirracchio R, et al. Epinephrine and short-term survival in cardiogenic shock: An individual data meta-analysis of 2583 patients. Intensive Care Med 2018; 44(6): 847-56.
[http://dx.doi.org/10.1007/s00134-018-5222-9] [PMID: 29858926]
[42]
Tarvasmäki T, Lassus J, Varpula M, et al. Current real-life use of vasopressors and inotropes in cardiogenic shock - adrenaline use is associated with excess organ injury and mortality. Crit Care 2016; 20(1): 208.
[http://dx.doi.org/10.1186/s13054-016-1387-1] [PMID: 27374027]
[43]
Levy B, Clere-Jehl R, Legras A, et al. Epinephrine Versus Norepinephrine for Cardiogenic Shock After Acute Myocardial Infarction. J Am Coll Cardiol 2018; 72(2): 173-82.
[http://dx.doi.org/10.1016/j.jacc.2018.04.051] [PMID: 29976291]
[44]
Oba Y, Lone NA. Mortality benefit of vasopressor and inotropic agents in septic shock: A Bayesian network meta-analysis of randomized controlled trials. J Crit Care 2014; 29(5): 706-10.
[http://dx.doi.org/10.1016/j.jcrc.2014.04.011] [PMID: 24857641]
[45]
Hajjar LA, Vincent JL, Barbosa Gomes Galas FR, et al. Vasopressin versus Norepinephrine in Patients with Vasoplegic Shock after Cardiac Surgery: The VANCS Randomized Controlled Trial. Anesthesiology 2017; 126(1): 85-93.
[http://dx.doi.org/10.1097/ALN.0000000000001434] [PMID: 27841822]
[46]
Dünser MW, Bouvet O, Knotzer H, et al. Vasopressin in Cardiac Surgery: A Meta-analysis of Randomized Controlled Trials. J Cardiothorac Vasc Anesth 2018; 32(5): 2225-32.
[http://dx.doi.org/10.1053/j.jvca.2018.04.006] [PMID: 29748077]
[47]
Currigan DA, Hughes RJ, Wright CE, Angus JA, Soeding PF. Vasoconstrictor responses to vasopressor agents in human pulmonary and radial arteries: An in vitro study. Anesthesiology 2014; 121(5): 930-6.
[http://dx.doi.org/10.1097/ALN.0000000000000430] [PMID: 25198173]
[48]
Poidinger B, Kotzinger O, Rutzler K, Kleinsasser A, Zierer A, Knotzer H. Intravenous Levosimendan and Vasopressin in New-Onset Acute Pulmonary Hypertension After Weaning from Cardiopulmonary Bypass. J Cardiothorac Vasc Anesth 2011; 33(2): 328-33.
[PMID: 30122612]
[49]
Wenzel V, Lindner KH, Krismer AC, Miller EA, Voelckel WG, Lingnau W. Repeated administration of vasopressin but not epinephrine maintains coronary perfusion pressure after early and late administration during prolonged cardiopulmonary resuscitation in pigs. Circulation 1999; 99(10): 1379-84.
[http://dx.doi.org/10.1161/01.CIR.99.10.1379] [PMID: 10077524]
[50]
Stadlbauer KH, Wenzel V, Krismer AC, Voelckel WG, Lindner KH. Vasopressin during uncontrolled hemorrhagic shock: Less bleeding below the diaphragm, more perfusion above. Anesth Analg 2005; 101(3): 830-2.
[http://dx.doi.org/10.1213/01.ANE.0000175217.55775.1C] [PMID: 16115999]
[51]
Post EH, Su F, Righy Shinotsuka C, et al. Renal autoregulation in experimental septic shock and its response to vasopressin and norepinephrine administration. J Appl Physiol 2018.
[http://dx.doi.org/10.1152/japplphysiol.00783.2017] [PMID: 30260750]
[52]
Gordon AC, Mason AJ, Thirunavukkarasu N, et al. Effect of Early Vasopressin vs Norepinephrine on Kidney Failure in Patients With Septic Shock: The VANISH Randomized Clinical Trial. JAMA 2016; 316(5): 509-18.
[http://dx.doi.org/10.1001/jama.2016.10485] [PMID: 27483065]
[53]
Freeman JG, Cobden I, Lishman AH, Record CO. Controlled trial of terlipressin (‘Glypressin’) versus vasopressin in the early treatment of oesophageal varices. Lancet 1982; 2(8289): 66-8.
[http://dx.doi.org/10.1016/S0140-6736(82)91689-0] [PMID: 6123808]
[54]
Liu ZM, Chen J, Kou Q, et al. Terlipressin versus norepinephrine as infusion in patients with septic shock: A multicentre, randomised, double-blinded trial. Intensive Care Med 2018; 44(11): 1816-25.
[http://dx.doi.org/10.1007/s00134-018-5267-9]
[55]
Morelli A, Ertmer C, Rehberg S, et al. Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): A randomized, controlled pilot study. Crit Care 2009; 13(4): R130.
[http://dx.doi.org/10.1186/cc7990] [PMID: 19664253]
[56]
Doerschug KC, Delsing AS, Schmidt GA, Ashare A. Renin-angiotensin system activation correlates with microvascular dysfunction in a prospective cohort study of clinical sepsis. Crit Care 2010; 14(1): R24.
[http://dx.doi.org/10.1186/cc8887] [PMID: 20175923]
[57]
Bucher M, Hobbhahn J, Kurtz A. Nitric oxide-dependent down-regulation of angiotensin II type 2 receptors during experimental sepsis. Crit Care Med 2001; 29(9): 1750-5.
[http://dx.doi.org/10.1097/00003246-200109000-00016] [PMID: 11546977]
[58]
Schmidt C, Höcherl K, Kurt B, Moritz S, Kurtz A, Bucher M. Blockade of multiple but not single cytokines abrogates downregulation of angiotensin II type-I receptors and anticipates septic shock. Cytokine 2010; 49(1): 30-8.
[http://dx.doi.org/10.1016/j.cyto.2009.10.006] [PMID: 19914088]
[59]
Tumlin JA, Murugan R, Deane AM, et al. Outcomes in Patients with Vasodilatory Shock and Renal Replacement Therapy Treated with Intravenous Angiotensin II. Crit Care Med 2018; 46(6): 949-57.
[http://dx.doi.org/10.1097/CCM.0000000000003092] [PMID: 29509568]
[60]
Suberviola B, Rodrigo E, González-Castro A, Serrano M, Heras M, Castellanos-Ortega Á. Association between exposure to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers prior to septic shock and acute kidney injury. Med Intensiva 2017; 41(1): 21-7.
[http://dx.doi.org/10.1016/j.medin.2016.07.010] [PMID: 28341094]
[61]
Fischer GW, Bengtsson Y, Scarola S, Cohen E. Methylene blue for vasopressor-resistant vasoplegia syndrome during liver transplantation. J Cardiothorac Vasc Anesth 2010; 24(3): 463-6.
[http://dx.doi.org/10.1053/j.jvca.2008.07.015] [PMID: 18835528]
[62]
Ozal E, Kuralay E, Yildirim V, et al. Preoperative methylene blue administration in patients at high risk for vasoplegic syndrome during cardiac surgery. Ann Thorac Surg 2005; 79(5): 1615-9.
[http://dx.doi.org/10.1016/j.athoracsur.2004.10.038] [PMID: 15854942]
[63]
Kirov MY, Evgenov OV, Evgenov NV, et al. Infusion of methylene blue in human septic shock: A pilot, randomized, controlled study. Crit Care Med 2001; 29(10): 1860-7.
[http://dx.doi.org/10.1097/00003246-200110000-00002] [PMID: 11588440]
[64]
Weiner MM, Lin HM, Danforth D, Rao S, Hosseinian L, Fischer GW. Methylene blue is associated with poor outcomes in vasoplegic shock. J Cardiothorac Vasc Anesth 2013; 27(6): 1233-8.
[http://dx.doi.org/10.1053/j.jvca.2013.02.026] [PMID: 23972738]
[65]
Mehaffey JH, Johnston LE, Hawkins RB, et al. Methylene Blue for Vasoplegic Syndrome After Cardiac Operation: Early Administration Improves Survival. Ann Thorac Surg 2017; 104(1): 36-41.
[http://dx.doi.org/10.1016/j.athoracsur.2017.02.057] [PMID: 28551045]
[66]
Hosseinian L, Weiner M, Levin MA, Fischer GW. Methylene Blue: Magic Bullet for Vasoplegia? Anesth Analg 2016; 122(1): 194-201.
[http://dx.doi.org/10.1213/ANE.0000000000001045] [PMID: 26678471]
[67]
Marik PE, Khangoora V, Rivera R, Hooper MH, Catravas J. Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Severe Sepsis and Septic Shock: A Retrospective Before-After Study. Chest 2017; 151(6): 1229-38.
[http://dx.doi.org/10.1016/j.chest.2016.11.036] [PMID: 27940189]
[68]
Donnino MW, Andersen LW, Chase M, et al. Randomized, Double-Blind, Placebo-Controlled Trial of Thiamine as a Metabolic Resuscitator in Septic Shock: A Pilot Study. Crit Care Med 2016; 44(2): 360-7.
[http://dx.doi.org/10.1097/CCM.0000000000001572] [PMID: 26771781]
[69]
Zabet MH, Mohammadi M, Ramezani M, Khalili H. Effect of high-dose Ascorbic acid on vasopressor’s requirement in septic shock. J Res Pharm Pract 2016; 5(2): 94-100.
[http://dx.doi.org/10.4103/2279-042X.179569] [PMID: 27162802]
[70]
Venkatesh B, Finfer S, Cohen J, et al. Adjunctive Glucocorticoid Therapy in Patients with Septic Shock. N Engl J Med 2018; 378(9): 797-808.
[http://dx.doi.org/10.1056/NEJMoa1705835] [PMID: 29347874]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 25
ISSUE: 19
Year: 2019
Page: [2133 - 2139]
Pages: 7
DOI: 10.2174/1381612825666190704101907
Price: $65

Article Metrics

PDF: 52
HTML: 6
EPUB: 2
PRC: 1

Special-new-year-discount